Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 16/20 | 0.52 |
| ▸ | ATXN2 | Q99700 | 13/20 | 0.52 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16962633 | 1.00 | ENPP2 (0.52) | ENPP2ATXN2DGAT2HTR2AABAT | |
| SCHEMBL16962851 | 0.92 | ENPP2 (0.49) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16963537 | 0.91 | ENPP2 (0.57) | ENPP2ATXN2DGAT2HTR2AABAT | |
| SCHEMBL16962687 | 0.91 | ENPP2 (0.57) | ENPP2ATXN2DGAT2HTR2AABAT | |
| SCHEMBL16963530 | 0.90 | ENPP2 (0.47) | ENPP2ATXN2DGAT2 | |
| SCHEMBL16962456 | 0.89 | ENPP2 (0.48) | ENPP2ATXN2DGAT2HTR2AABAT | |
| SCHEMBL16963046 | 0.87 | ENPP2 (0.45) | ENPP2ATXN2DGAT2HTR2AABAT | |
| SCHEMBL16962387 | 0.87 | ENPP2 (0.45) | ENPP2ATXN2DGAT2HTR2AABAT | |
| SCHEMBL16963188 | 0.87 | ENPP2 (0.45) | ENPP2ATXN2DGAT2CA2 | |
| SCHEMBL21313892 | 0.86 | ENPP2 (0.63) | ENPP2ATXN2DGAT2HTR2AABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |